UniCredit shares closed 3.3% lower. AstraZeneca lost 1.7% after its experimental precision drug developed with Daiichi Sankyo ...
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...
A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...
It is a fictional representation created for illustrative purposes only. AstraZeneca's experimental precision drug, developed ...
It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
Intel jumps on reports of Apollo investment and Qualcomm takeover interest, Palantir and Dell join the S&P 500, and TSMC and Samsung reportedly mulling UAE chip megafactories. Here's what investors ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
European stock markets were up at midday as investors digested eurozone survey results, while Commerzbank shares were in focus after the German government decided to keep its stake in the lender.
AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback